Key Points
- Intuitive Surgical VP Fredrik Widman sold 1,089 shares for approximately $407,765 at an average price of $374.44 under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 51.49% to 1,026 shares.
- The company reported stronger-than-expected quarterly results, with EPS of $2.80 versus the $2.48 consensus and revenue of $2.89 billion, up 18.4% year over year.
- Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $508.68, while institutional investors own 83.64% of the stock.
Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) VP Fredrik Widman sold 1,089 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the transaction, the vice president owned 1,026 shares of the company's stock, valued at approximately $384,175.44. This represents a 51.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Intuitive Surgical Stock Up 1.4%
ISRG stock opened at $382.29 on Thursday. The stock has a 50-day simple moving average of $373.52 and a two-hundred day simple moving average of $420.74. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The firm has a market capitalization of $135.06 billion, a PE ratio of 43.79, a PEG ratio of 2.85 and a beta of 1.47.
Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.48 by $0.32. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.81 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.
Institutional Trading of Intuitive Surgical
Several hedge funds have recently added to or reduced their stakes in ISRG. Deutsche Bank AG boosted its holdings in Intuitive Surgical by 9.6% during the 4th quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider's stock valued at $862,108,000 after acquiring an additional 132,966 shares during the period. Jag Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth approximately $18,771,000. Plato Investment Management Ltd bought a new position in shares of Intuitive Surgical in the second quarter worth approximately $4,315,000. Sycomore Asset Management purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $10,730,000. Finally, Hikari Power Ltd purchased a new position in shares of Intuitive Surgical in the second quarter worth $5,619,000. 83.64% of the stock is owned by institutional investors.
Key Headlines Impacting Intuitive Surgical
Here are the key news stories impacting Intuitive Surgical this week:
- Positive Sentiment: Intuitive Surgical received a European CE mark expanding the da Vinci SP system’s approved use to transvaginal gynecologic procedures. The authorization opens a new women’s-health market and could broaden the platform’s long-term growth runway in Europe. ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
- Positive Sentiment: A meta-analysis covering approximately 14 million procedures reported better perioperative outcomes for da Vinci surgery across 13 common conditions compared with laparoscopic and open surgery. The findings may support broader adoption of robotic-assisted surgery. ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
- Positive Sentiment: Analyst commentary remains generally constructive, with recent Buy ratings and a reported median price target of $574, substantially above the stock’s current trading level. Investors are also watching the company’s strong procedure-volume trends and prior quarterly revenue growth of more than 18%.
- Positive Sentiment: Social-media discussions identified a potential double-bottom pattern, fueling speculation that the recent decline could precede a rebound if third-quarter results show continued growth in da Vinci procedures and system installations. Opinions on Recent Price Decline Ahead of Q3 Earnings
Analysts Set New Price Targets
A number of research firms have recently commented on ISRG. Citigroup reduced their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating for the company in a research report on Friday, July 17th. Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. Bank of America dropped their price objective on Intuitive Surgical from $520.00 to $515.00 in a research note on Friday, June 12th. Raymond James Financial restated an "outperform" rating and set a $483.00 target price (down from $577.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. Finally, Truist Financial decreased their target price on Intuitive Surgical from $580.00 to $510.00 and set a "buy" rating on the stock in a research note on Thursday, July 16th. Twenty-two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $508.68.
Read Our Latest Stock Analysis on Intuitive Surgical
Intuitive Surgical Company Profile
(
Get Free Report)
Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.
The company's principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
